Venus launches patented research product “ACHNIL” in India
Once-a-day painkiller immediately relieves and is effective for 24 hours
Chandigarh Monday, July 11, 2011- Venus Remedies Limited, a leading research based global pharmaceutical company and amongst the prominent injectables manufacturers in the world, launched a novel formulation “ACHNIL” brand of “Aceclofenac- injection” in India. “ACHNIL” injection is a “single Shot… last day long” formulation.
Dr. Manu Chaudhry, Joint Managing Director of the company on the occasion said, “This novel formulation based on NDDS (Novel Drug Delivery System) technology will fill in the gap of long standing demand for better pain management therapies especially for aged population. It is not only going to reduce the number of pricks but will also drastically reduce the side effects associated with the use of NSAIDs.” Discussing about the benefits of the drug Ms. Chaudhary added, “ACHNIL acts directly by giving instant relief from acute pain and is effective for the next 24 hours against the conventional daily dose of three injections of diclofenac given every 8 hours.”
The development of ACHNIL commenced at VMRC and took more than seven years in the successful completion of phase-I, phase-II and phase-III clinical trials and regulatory approvals from DCGI for this product.
The marketing team of Venus is fully geared upon all India launch to take this innovative pain solution drug in most needed Indian market. “The Indian market for pain management is approximately INR 2000 crores which is growing at the rate of 16% – 20% annually and is expected to be of INR 3500 crores by 2015. Venus is expecting substantial shares in the coming years” said Mr. Peeyush Jain, Deputy Managing Director and head Marketing unit of Venus.
ACHNIL ensures immediate burst release action, which gives results with in 4-5 minutes and rest drug is released in controlled manner thereby passing the true benefits of Aceclofenac.
Aceclofenac is a radical innovation of Venus Medicine Research Centre which is a non steroidal anti-inflammatory drug (NSAID) and is used to relieve acute as well as chronic pain and inflammation in rheumatoid arthritis, osteoarthritis, low back pain, ankylosing spondylitis, dental pain, post traumatic pain, gynecological pain and oncology pain. Aceclofenac is designed in such a way that the product is never released in super or sub therapeutic zones and hence is highly safe and practically free from side effects.
Venus has already secured patents from India as well as from Europe for this research product which are valid up to 2025 and will further reinforce the market position of Venus Remedies in India and the major European economies such as Germany, UK, France, Spain, Sweden, Italy and Switzerland.
The global market for pain management is forecast to reach US$60 billion by the year 2015. Currently, more than 1.5 billion people worldwide suffer from chronic pain of varying degrees. Among all types of chronic pains, neuropathic pain stands as the highly underserved market. Approximately 3-4.5% of the global population suffers from neuropathic pain, with incidence rate increasing in complementary to age.
Venus plans to launch ACHNIL in other market worldwide.
About Venus Remedies Ltd.:
Venus Remedies Ltd is research and development driven pharmaceutical manufacturing company. Among the top 50 Indian Pharma companies of India, the company has outpaced most Indian pharmaceutical companies in its growth and value creation over the past few years.
Driven by a top class team of managers and motivators this organization is counted as one of the most professional companies of India and a preferred place for top innovators and managers to join the bandwagon of the globally significant Indian Pharma industry.
Venus Remedies Ltd is BSE & NSE listed company with turnover of 310 crores (FY 2010) is present in 60 regulated and semi-regulated countries, actively exporting to more than 20 countries.
The company has two manufacturing locations in India and one in Germany. Venus is top class manufacturer of Oncological and Cephalosporin Injectable products following EU-GMP norms for all is activities. It has 11 overseas offices, 1 R&D center and competent staff of more than 1500 employees. VMRC is the R & D wing of Venus Remedies Limited, approved by Department of Scientific & Industrial Research (DSIR), Govt. of India. VMRC is recognised for development of globally competitive Technologies of high commercial potential.
Venus has a broad range of products catering to critical care segment in parenterals like cephalosporins, carbapenems and oncology drugs in lyophilized form, infusions and small volume parenterals.
The research team of Venus has proved itself to be a power house of innovation by filing many international patents for sophisticated formulations of anti-biotics and oncological therapeutics.
In May 2010 and recently in May 2011 for consecutive second year in a row Venus has won Gold Medal in DST-Lockheed Martin India Innovation Growth Program. This year for TROIS, an integrated medicinal research product and earlier for Ampucare, a wound care product. The program is conducted in association with Department of Science and Technology, Govt. of India, Lockheed Martin Corporation, Indo-U.S. Science and Technology forum, FICCI and IC2 institute (The University of Texas in Austin). This is a reputed forum to assist Indian innovators to commercialise their technologies across globe.
Venus Remedies is aiming to create intellectual property wealth of one billion US dollar.